The mother of a six-year-old girl with a rare neurodegenerative disease has urged health bosses to "do the right thing" amid ...

BioMarin Pharmaceutical (BMRN) closed the last trading session at $70.49, gaining 10.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...

As Rare Disease Day is commemorated on 28 February, experts discuss the barriers to gene therapy access for some rare diseases.

BioMarin’s Voxzogo has been shown to increase growth rates in children with hypochondroplasia, a genetic cause of very short stature, in a phase 2 trial. Hypochondroplasia is a form of skeletal ...

BioMarin Pharmaceutical (Nasdaq: BMRN) reported $747.31 million in revenue for the fourth quarter, a 16% year-over-year increase. The San Rafael-based global producer of genetic treatments for ...

If you’re on the fence about investing in argenx SE or BioMarin Pharmaceutical Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a biotechnology company specializing in therapies for rare genetic diseases with a market capitalization of $13.15 billion, has been navigating a ...

For the fall/winter 2025 season in London, designers incorporated vibrant shades of color, such as blues and maroons, along with a variety of prints, like bold florals and classic plaids.

BioMarin Pharmaceutical (TADAWUL:2070) Inc. (NASDAQ:BMRN), a pharmaceutical company with a market capitalization of $13.15 billion, announced on Monday the appointment of Timothy P. Walbert to its ...